{
    "Rank": 341,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT03908671",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "STZD-1801"
                },
                "Organization": {
                    "OrgFullName": "Stemirna Therapeutics",
                    "OrgClass": "INDUSTRY"
                },
                "BriefTitle": "Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer",
                "OfficialTitle": "Clinical Trial on the Safety and Efficacy of Neoantigen Antigen mRNA Tumor Vaccine in the Treatment of Advanced Esophageal Cancer and Non-small Cell Lung Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "April 2023",
                "OverallStatus": "Recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "October 18, 2019",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "October 31, 2024",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "December 31, 2025",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "April 8, 2019",
                "StudyFirstSubmitQCDate": "April 8, 2019",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "April 9, 2019",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "April 11, 2023",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "April 13, 2023",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Stemirna Therapeutics",
                    "LeadSponsorClass": "INDUSTRY"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "The First Affiliated Hospital of Zhengzhou University",
                            "CollaboratorClass": "OTHER"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes",
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal cancer and non-small cell lung cancer",
                "DetailedDescription": "Primary objectives:\n\nAssessing the safety and tolerability of mRNA personalized tumor vaccines encoding neoantigen for unresectable or metastatic advanced esophageal and non-small cell lung cancers with standard treatment failure or no standard treatment.\n\nSecondary objectives:\n\nPreliminary observation of the efficacy of mRNA personalized tumor vaccines encoding neoantigen for unsurgically resected or metastatic advanced esophageal and non-small cell lung cancers with standard treatment failure or no standard treatment.\n\nTime of tumor progression (TTP); Disease Control Rate (DCR); Objective Remission Rate (ORR); Overall Survival (OS)."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Esophageal Cancer",
                        "Non Small Cell Lung Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "mRNA cancer vaccine",
                        "cancer vaccine",
                        "tumor vaccine",
                        "NSCLC",
                        "Esophageal Cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Not Applicable"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "24",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Personalized mRNA Tumor Vaccine",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with advanced esophageal and non-small cell lung cancers",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: Personalized mRNA Tumor Vaccine"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "Personalized mRNA Tumor Vaccine",
                            "InterventionDescription": "subcutaneous injection with personalized mRNA tumor vaccine",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Personalized mRNA Tumor Vaccine"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Number of participants with treatment-related adverse events as assessed by CTCAE v4.03",
                            "PrimaryOutcomeDescription": "During the trial conduction, especially within the 24 weeks of treatment phase when mRNA tumor Vaccine administered, all adverse events (including laboratory abnormality and clinical events) will be closely monitored, and all \u2265 grade 3 adverse events per CTCAE will be recorded, including but not limited to the toxicities potentially suspected to relate to injection procedures and/or mRNA Tumor Vaccine therapy as listed below:\n\nFever Chills Nausea, vomiting and other gastrointestinal symptoms Fatigue Hypotension Respiratory distress Tumor lysis syndrome Neutropenia, thrombocytopenia Liver and kidney dysfunction Neutropenia, thrombocytopenia Liver and kidney dysfunction",
                            "PrimaryOutcomeTimeFrame": "24 weeks"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Disease Control Rate (DCR)",
                            "SecondaryOutcomeDescription": "Disease Control Rate of Personalized mRNA Tumor Vaccine",
                            "SecondaryOutcomeTimeFrame": "1.5 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Progression-free Survival (PFS)",
                            "SecondaryOutcomeDescription": "Progression-free Survival of Personalized mRNA Tumor Vaccine",
                            "SecondaryOutcomeTimeFrame": "2 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Time to Tumor Progression (TTP)",
                            "SecondaryOutcomeDescription": "Time to Tumor Progression of Personalized mRNA Tumor Vaccine",
                            "SecondaryOutcomeTimeFrame": "2 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Overall Survival (OS)",
                            "SecondaryOutcomeDescription": "Overall Survival of Personalized mRNA Tumor Vaccine",
                            "SecondaryOutcomeTimeFrame": "3 years"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nAged between 18 and 75 (including both ends), with no gender limit;\nThe primary lesion was confirmed by histopathology or cytology as esophageal carcinoma (\u2162C (T4bNanyM0, TanyN3M0), and stage \u2163) or non-small cell lung cancer (stage \u2162B-\u2163).\nPatients who have metastatic or locally advanced tumor but failed instandard treatments or not suitable for standard treatments;\nAccording to RECIST (V1.1), the efficacy evaluation criteria for solid tumors, there is at least one measurable lesion.\nParticipants with Performance Scale (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) PS\nParticipants must have at least 1 lesion amenable to the mandatory fresh tumor biopsy at study entry\nFertile patients must agree to use a reliable contraceptive methods (hormonal or barrier methods or abstinence) during the trial and for at least 12 weeks after the last treatment;\nThe subject voluntarily participates and signs ICF (Informed consent forms).\n\nExclusion Criteria:\n\nAny clinical research drugs, anti-cancer monoclonal antibodies, anti-cancer therapeutic vaccines, immunostimulants (such as IL-2) or using previous investigational drugs within 7 days of the first treatment with mRNA-personalized tumor vaccine or carrelizumab.\nPatients who have allergies or previous history of biological drug allergy;\nPatients who are in pregnant or breast-feeding;\nPatients who are expected to survive less than 3 months during the screening period;\nTumor mutation load (TMB) is less than 2.0/Mb or tumor neogenic antigen load (TNB) is less than 0.5/Mb or the number of predicted neoantigen is less than 3;\nPatients who underwent major surgery or suffered significant trauma within 4 weeks prior to the enrollment (blood collection), or who are expected to undergo major surgery during the study period;\nPatients with symptoms of brain metastases (Patients with stable brain metastases can be included)\nExtensive lung metastases from tumors, causing breathing difficulties;\nPatients who have tumors close to large blood vessels or nerves;\nA history of severe cardiovascular and cerebrovascular diseases, including but not limited to ventricular arrhythmia requiring clinical intervention; Acute coronary syndrome, myocardial infarction, congestive heart failure, stroke or other grade III and above cardiovascular events within 6 months; New York Heart Association (NYHA) cardiac function grade\u2265Grade II or left ventricular ejection fraction (LVEF) <50%; Poorly controlled hypertension after standard treatment (systolic blood pressure> 150 mmHg and diastolic blood pressure> 90 mmHg);\nPatients with active ulcers and gastrointestinal bleeding;\nPatients with clinically confirmed autoimmune disease have received systemic treatment in the past 2 years; HIV, HCV positive; HBV-DNA\u22651\u00d7103 copies/mL (or 2\u00d7102 IU/mL); Acute EBV or CMV virus infection;\nPatients with previous history of non-infectious pneumonia requiring steroid therapy or acute lung cancer;\nParticipants with a history of interstitial lung disease;\nPatients who have a history of organ transplantation or are waiting for organ transplantation;\nHave any uncontrolled active infection;\nImmunosuppressed subjects, including those with known immunodeficiency; those who are currently using steroids systemically (except those who are using inhaled steroids recently or currently);\nSkin diseases (such as psoriasis) may prevent intradermal vaccines from reaching the target area;\nWho have received chemotherapy, biotherapy, radiotherapy, endocrine therapy, targeted therapy and other tumor treatments, or other experimental drug treatments, or surgery (excluding diagnostic biopsy) within 7 days prior to the first administration of mRNA tumor vaccine treatment;\nAdverse effects from previous antitumor therapy have not recovered referred to CTCAE (V5.0) rating \u22641 (except hair loss);\nThe investigator evaluates that the subject is unable or unwilling to comply with the requirements of study protocol.",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "MaximumAge": "75 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "CentralContactList": {
                    "CentralContact": [
                        {
                            "CentralContactName": "Li Yang",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "0371-66295320",
                            "CentralContactEMail": "yanglizzuyl@163.com"
                        },
                        {
                            "CentralContactName": "Yi Zhang",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "0371-66295219",
                            "CentralContactEMail": "yizhang001@163.com"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "The First Affiliated Hospital of Zhengzhou University",
                            "LocationStatus": "Recruiting",
                            "LocationCity": "Zhengzhou",
                            "LocationState": "Henan",
                            "LocationCountry": "China",
                            "LocationContactList": {
                                "LocationContact": [
                                    {
                                        "LocationContactName": "Yi Zhang, Doctor",
                                        "LocationContactRole": "Contact",
                                        "LocationContactPhone": "15138928971",
                                        "LocationContactEMail": "yizhang00@163.com"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "Undecided"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000008175",
                            "ConditionMeshTerm": "Lung Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000002289",
                            "ConditionMeshTerm": "Carcinoma, Non-Small-Cell Lung"
                        },
                        {
                            "ConditionMeshId": "D000004938",
                            "ConditionMeshTerm": "Esophageal Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000012142",
                            "ConditionAncestorTerm": "Respiratory Tract Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000013899",
                            "ConditionAncestorTerm": "Thoracic Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000008171",
                            "ConditionAncestorTerm": "Lung Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012140",
                            "ConditionAncestorTerm": "Respiratory Tract Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000002283",
                            "ConditionAncestorTerm": "Carcinoma, Bronchogenic"
                        },
                        {
                            "ConditionAncestorId": "D000001984",
                            "ConditionAncestorTerm": "Bronchial Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000005770",
                            "ConditionAncestorTerm": "Gastrointestinal Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004067",
                            "ConditionAncestorTerm": "Digestive System Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000006258",
                            "ConditionAncestorTerm": "Head and Neck Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004066",
                            "ConditionAncestorTerm": "Digestive System Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000004935",
                            "ConditionAncestorTerm": "Esophageal Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005767",
                            "ConditionAncestorTerm": "Gastrointestinal Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M10862",
                            "ConditionBrowseLeafName": "Lung Neoplasms",
                            "ConditionBrowseLeafAsFound": "Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M5236",
                            "ConditionBrowseLeafName": "Carcinoma, Non-Small-Cell Lung",
                            "ConditionBrowseLeafAsFound": "Non-Small Cell Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M7778",
                            "ConditionBrowseLeafName": "Esophageal Neoplasms",
                            "ConditionBrowseLeafAsFound": "Esophageal Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M5224",
                            "ConditionBrowseLeafName": "Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14669",
                            "ConditionBrowseLeafName": "Respiratory Tract Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M16348",
                            "ConditionBrowseLeafName": "Thoracic Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10858",
                            "ConditionBrowseLeafName": "Lung Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14667",
                            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5230",
                            "ConditionBrowseLeafName": "Carcinoma, Bronchogenic",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4950",
                            "ConditionBrowseLeafName": "Bronchial Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8576",
                            "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6946",
                            "ConditionBrowseLeafName": "Digestive System Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M9038",
                            "ConditionBrowseLeafName": "Head and Neck Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6945",
                            "ConditionBrowseLeafName": "Digestive System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8573",
                            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7775",
                            "ConditionBrowseLeafName": "Esophageal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T2141",
                            "ConditionBrowseLeafName": "Esophageal Cancer",
                            "ConditionBrowseLeafAsFound": "Esophageal Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC08",
                            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC06",
                            "ConditionBrowseBranchName": "Digestive System Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M17050",
                            "InterventionBrowseLeafName": "Vaccines",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}